Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2010-09-30
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protected Pea Protein Extract and Satiety Hormone Release
NCT01877057
Acute Fatty Acid Intervention Study (AFAST)
NCT01000194
Different Dosages of Bioactive Wheat Peptides and Blood Pressure Level and CVD Risk Biomarkers in Healthy Subjects
NCT02197910
Effects of Peanut Consumption on Postprandial Inflammation, Glucose and Triglycerides
NCT01173042
Yellow Pea Protein and Fibre and Short Term Food Intake
NCT01255085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High-fat shake with Pea protein
Shake containing 95 gram of fat, additive 30 gram pea protein
High-fat shake with Pea protein hydrolysate
Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
High-fat shake - Control
Shake containing 95 gram of fat, no protein additive
High-fat shake with Gluten protein
Shake containing 95 gram of fat, additive 30 gram gluten protein.
High-fat shake with Gluten protein hydrolysate
Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* central obesity: waist circumference ≥94 cm
plus any one of the following four factors:
* raised triglyceride level: ≥1.7 mmol/L;
* reduced high-density lipoprotein (HDL) cholesterol: \<1.03 mmol/L
* raised blood pressure: systolic blood pressure ≥130 mmHg or diastolic BP ≥85 mmHg or use of blood pressure lowering medication
* raised fasting plasma glucose ≥ 5.6 mmol/L
* age 45-70 years
* body weight should be stable for 3 months
* stable exercise habits during the last 6 months, and not participating in any vigorous exercise program
Exclusion Criteria
* (undiagnosed) diabetes - but not impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) as evaluated by an oral glucose tolerance test at screening
* active hearth disease, i.e. history of myocardial infarction or angina pectoris
* following, or have recently followed a (weight-loss) diet
* drug uses knowing to interfere with the objectives of the study
* oral corticosteroids, lipid-lowering drugs (statins)
* allergic to cow milk / dairy products or gluten
* vegetarians
* received inoculations within 2 months of starting or planned to during the study
* donated or intended to donate blood 2 months before till two months after the study
* abuse of drugs and/or alcohol
* participation in another biomedical study within 1 month before the first screening visit
* not agreeable to be informed about possible distorted blood values which could be found by screening
45 Years
70 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wageningen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wageningen University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marco Mensink, Dr
Role: STUDY_CHAIR
Department Human Nutrition, Wageningen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wageningen University, Division of Human Nutrition
Wageningen, Gelderland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL3207808110
Identifier Type: OTHER
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.